Qiagen shares hit hardest day in over 5 years on outlook downgrade, weak Q1 results

Qiagen NV

28/04/2026 08:26

** Shares in Netherlands-based biotechnology company Qiagen QIA.DE fall 7%, heading for their worst session in more than five years, after full-year outlook cut, weaker Q1 results

** Qiagen now expects FY revenue growth of between 1% and 2% vs 5% before; adjusted diluted EPS to be at least $2.43 vs $2.51 seen before

** Outlook downgrade is driven by weaker QuantiFERON immigration testing demand, ongoing caution among U.S. life sciences customers, and rising geopolitical uncertainty, the company says

** Q1 net sales were $492 million vs $500 million expected by Vara consensus

** The Q1 print was a surprise, Jefferies says

** "Absent notable prudence on the guide, expect the stock to be down," the broker says

** Including Tuesday's loss, the stock is down 22% this year

 (Reporting by Amir Orusov)

 ((Amir.orusov@thomsonreuters.com))